Psoriasiform dermatitis induced by dupilumab successfully treated with upadacitinib

Dermatol Ther. 2022 Nov;35(11):e15788. doi: 10.1111/dth.15788. Epub 2022 Sep 4.

Authors

Cataldo Patruno¹, Gabriella Fabbrocini², Mario De Lucia², Vincenzo Picone², Lucia Genco², Maddalena Napolitano³

Affiliations

¹ Department of Health Sciences, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
² Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
³ Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.

PMID: 36001502
DOI: 10.1111/dth.15788

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Eczema*
Heterocyclic Compounds, 3-Ring
Humans
Treatment Outcome

Substances

dupilumab
upadacitinib
Antibodies, Monoclonal, Humanized
Heterocyclic Compounds, 3-Ring